Prognostic impact of FOXP3 expression in triple-negative breast cancer

References

• Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, . Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429–34.
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, . Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492–502.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373–80.
   PubMed Web of Science ®Google Scholar
• Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, . FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009;27:1746–52.
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, . An evaluation of the clinical significance of FOXP3(+) infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011;127:99–108.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–9.
   PubMed Web of Science ®Google Scholar
• Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404–8.
   PubMed Web of Science ®Google Scholar
• Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, . CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009;131: 109–18.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, . Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008;98:1258–63.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186–92.
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, . Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444–53.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, . Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586–93.
   PubMed Web of Science ®Google Scholar
• Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, . Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008;34:173–9.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423–34.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, . Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;125:65–72.
   PubMed Web of Science ®Google Scholar
• Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, . Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681–91.
   PubMed Web of Science ®Google Scholar
• Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, . Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol 2011;68:753–61.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416–22.
   PubMedGoogle Scholar
• Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: Current controversies and future perspectives. Eur J Immunol 2006;36:2832–6.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245–53.
   PubMed Web of Science ®Google Scholar
• Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, . Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003;112:1437–43.
   PubMed Web of Science ®Google Scholar
• Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, . FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007;117:3765–73.
   PubMed Web of Science ®Google Scholar
• Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007;129:1275–86.
   PubMed Web of Science ®Google Scholar
• Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, . Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 2011;22:1554–60.
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167–74.
   PubMed Web of Science ®Google Scholar
• Disis ML, Lyerly HK. Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 2005;23:8923–5.
   PubMed Web of Science ®Google Scholar
• Wolf AM, Rumpold H, Wolf D, Gastl G, Reimer D, Jenewein N, . Role of forkhead box protein 3 expression in invasive breast cancer. J Clin Oncol 2007;25:4499–500; author reply 500–1.
   PubMed Web of Science ®Google Scholar
• Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: A potential therapeutic target. Mod Pathol 2008;21: 1527–32.
   PubMed Web of Science ®Google Scholar
• Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, . CD8 cytotoxic T cell and FOXP3 regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011;130:645–55.
   PubMed Web of Science ®Google Scholar
• Wang J, Ray PS, Sim MS, Zhou XZ, Lu KP, Lee AV, . FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappaB signaling. Oncogene Epub 2012 Jan 16.
   Google Scholar
• Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ, . BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene 2012;31:3667–78.
   PubMed Web of Science ®Google Scholar
• Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, . Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344–50.
   PubMed Web of Science ®Google Scholar
• Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, . CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 2007;13:2714–21.
   PubMed Web of Science ®Google Scholar